Neo Ivy Capital Management has recently made an investment in
Lam Research Corporation (LRCX), despite the stock's falling value. This bio-tech firm, highly favored by billionaires, represents an exemplar of the Growth at a Reasonable Price (GARP) strategy.
First Trust Advisors LP and
Orion Portfolio Solutions added LRCX shares to their portfolios. LRCX's growth and readiness for expansion are suggested by crossing above the 50-Day Moving Average and exceeding market returns. Conversely, the company's share price dropped by 3.7% following insider selling.
Ava Harter and
Douglas Bettinger, CFO, both sold a significant amount of shares. Despite the insider selling and price drop, Wall Street analysts view LRCX as a potential for 25.43% surge. The case for the company isn't perfectly bullish, with the stock underperforming compared to competitors on some days. Yet, LRCX benefits significantly from AI. Furthermore, LRCX strengthened its position with leadership transitions focused on speeding company growth towards the AI era. Despite the uncertainties,
Jim Cramer sees LRCX as the future.
Lam Research Corp LRCX News Analytics from Thu, 21 Aug 2025 07:00:00 GMT to Sat, 07 Mar 2026 12:12:38 GMT -
Rating 0
- Innovation 6
- Information 8
- Rumor -3
